Business description
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
Management board & Supervisory board
| CEO |
| Jean-Jacques Bienaimé |
| Management board |
| Brian Mueller, Amy Wireman, Dr. Brinda Balakrishnan, Dr. C. Greg Guyer, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Philip Lo Scalzo |
| Supervisory board |
| Jean-Jacques Bienaimé, David Pyott, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Mark Alles, Maykin Ho, Richard A. Meier, Robert Hombach, Willard H. Dere |
Company data
| Name: |
Biomarin Pharmaceutical Inc. |
| Address: |
770 Lindaro Street,San Rafael, California 94901, USA |
| Phone: |
+1-415-506-6700 |
| Fax: |
+1-415-3827889 |
| E-mail: |
-
|
| Internet: |
www.bmrn.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
58.89% |
| IPO date: |
7/1/1999 |
Investor relations
| Name: |
Traci McCarty |
| IR phone: |
+1-415-455-7558 |
| IR Fax: |
- |
| IR e-mail: |
IR@BMRN.com
|
